Navigation Links
Caliper Life Sciences to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19
Date:7/18/2011

HOPKINTON, Mass., July 18, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for life science companies, today announced that Kevin Hrusovsky, President and CEO, has been invited to ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19th and will be joined by family, management and several strategic customers to participate in this special event. This event highlights Caliper's successful transformation into a leading diversified life sciences tools company.  

Caliper's strategy is to commercialize disruptive technologies that revolutionize and personalize health care through improved patient diagnosis, prognosis and treatment by developing market-leading tools and services for pre-clinical and clinical imaging, digital pathology, sample preparation for next generation sequencing, molecular and companion diagnostics, stem cell research, as well as the development of biotherapeutics and vaccines.  Over the past seven years, Caliper has grown core products and services, increased margins and become operating cash flow positive by completing several strategic acquisitions and  divesting non-core product lines.  Caliper reported organic revenue growth of over 20% in the first quarter of 2011.  The market has rewarded Caliper's success with an increase in its stock price during each of 2009 and 2010 of over 150%, and an approximate 30% increase year-to-date in 2011.  

"Ringing the Opening Bell is a great opportunity to recognize our families, employees, customers, collaborators and investors for their dedicated support in building Caliper into a successful high growth company with strong potential for making life changing impact in health care.  Their hard work and inspiring 'can do' attitudes have enabled Caliper to become a diversified, high growth tools provider with attractive short- and long-term prospects," said Kevin Hrusovsky, President and CEO of Caliper.  "We are excited about our future as we launch important products into attractive markets designed to revolutionize and personalize medicine and transform 'sick care' to health care.  We believe Caliper's product and technology platforms have the potential to increase our annual organic revenue growth to 15% or greater, with incremental revenues contributing at least 60% of revenue to operating margin."  

A live webcast of The NASDAQ Stock Market Opening Bell can be viewed at: http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com, as well as live on major broadcast news outlets including CNBC, FOX Business Network, Reuters TV, and Bloomberg TV.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.  Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

The statements in this press release regarding future events, including Caliper's belief that its product and technology platforms will enable Caliper to increase its annual organic revenue growth to 15% or greater, with incremental revenues contributing at least 60% of revenue to operating margin, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended.  These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that Caliper's expectations regarding demand for its products and services may not materialize if capital spending by Caliper's customers declines, if customers do not purchase newly developed or acquired product lines as rapidly as Caliper believes that they will, or if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its microfluidic and imaging systems and products and its assay development and services product offerings.  Further information on risks faced by Caliper are detailed under the caption "Risks Related to Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2010. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

Caliper is a registered trademark of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
2. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
3. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
4. Caliper Awarded New Task Order for EPA ToxCast Program
5. Caliper Life Sciences Introduces Sciclone(R) G3 Liquid Handler
6. Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
7. Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic
8. Caliper Life Sciences Forms Scientific Advisory Board for Next Generation Sequencing
9. Caliper Life Sciences Fourth Quarter 2009 Financial Results Conference Call Notice
10. Caliper Life Sciences and Stanford University File a Patent Infringement Lawsuit Against Carestream Health, Inc.
11. Caliper Settles Outstanding Litigation with Shimadzu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):